

Applicants: Eric Kandel, et al.
U.S. Serial No.: 10/582,303
Filed: May 11, 2007
Page 2

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

What is claimed is:

1. (Original) A method for treating a subject afflicted with a fear-related disorder comprising administering to the subject a therapeutically effective amount of a gastrin-releasing peptide receptor agonist.
2. (Original) The method of claim 1, wherein the subject is human.
3. (Original) The method of claim 1, wherein the fear-related disorder is a phobia.
4. (Original) The method of claim 1, wherein the fear-related disorder is chronic anxiety.
5. (Original) The method of claim 1, wherein the fear-related disorder is a panic attack.
6. (Original) The method of claim 1, wherein the fear-related disorder is post-traumatic stress disorder.
7. (Original) The method of claim 1, wherein the fear-related

disorder is autism.

8. (Original) A method for inhibiting in a subject the onset of a fear-related disorder resulting from exposure to a traumatic experience comprising administering a prophylactically effective amount of a gastrin-releasing peptide receptor agonist to the subject prior to and/or following the traumatic experience.
9. (Original) The method of claim 8, wherein the subject is human.
10. (Original) The method of claim 8, wherein the fear-related disorder is a phobia.
11. (Canceled)
12. (Original) The method of claim 8, wherein the fear-related disorder is a panic attack.
13. (Original) The method of claim 8, wherein the fear-related disorder is post-traumatic stress disorder.
14. (Original) The method of claim 8, wherein the agonist is administered to the subject prior to the traumatic experience.
15. (Original) The method of claim 14, wherein the traumatic experience is military combat.
16. (Original) The method of claim 8, wherein the agonist is

administered to the subject after the traumatic experience.

17. (Original) The method of claim 16, wherein the traumatic experience is a physical assault.
18. (Canceled)
19. (Original) A nucleic acid comprising a gastrin-releasing peptide gene, wherein the gene has inserted into it, either at its start or stop codon, a polypeptide-encoding sequence, wherein the polypeptide is not gastrin-releasing peptide.
20. (Currently Amended) A bacterial artificial chromosome (BAC) comprising the nucleic acid of claim 20 19.
- 21.-24. (Canceled)
25. (New) An article of manufacture comprising (a) a packaging material having therein a gastrin-releasing peptide receptor agonist, and (b) a label indicating a use for the agonist in treating, and/or inhibiting the onset of, a fear-related disorder in a subject.
26. (New) A transgenic animal whose somatic cells have stably integrated therein a nucleic acid comprising a gastrin-releasing peptide gene, wherein the gene has inserted into it, either at its start or stop codon, a polypeptide-encoding sequence, wherein the polypeptide is not gastrin-releasing peptide, and wherein the polypeptide is specifically expressed in the animal's amygdale.

Applicants: Eric Kandel, et al.
U.S. Serial No.: 10/582,303
Filed: May 11, 2007
Page 5

27. (New) A method for producing a transgenic animal whose amygdaloid cells specifically expresss an exogenous polypeptide, which method comprises producing a transgenic animal by introducing into an oocyte an exogenous DNA so that the exogenous DNA is stably integrated into the oocyte, and permitting the resulting oocyte to mature into a viable animal, wherein (a) the animal's somatic cells have the exogenous DNA stably integrated therein, (b) the exogenous DNA comprises a gastrin-releasing peptide gene, wherein the gene has inserted into it, either at its start or stop codon, an exogenous polypeptide is not gastrin-releasing peptide, and (c) the exogenous polypeptide is specifically expressed in the animal's amygdale.